EpiVax and Massachusetts General Hospital Advance on T cell-Targeted Epitope Vaccine for Q Fever

by Elena Iemma | May 25, 2022 | News

PROVIDENCE, RI, May 25, 2022 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) announces the publication “Evaluation of a Human T Cell-Targeted Multi-Epitope Vaccine for Q Fever in Animal Models of Coxiella burnetii Immunity” in Frontiers in Immunology, a collaboration...

EpiVax Identifies T cell Epitopes critical to robust T cell immune response in SARS-CoV-2 , Results Published in NPJ Vaccines

by Elena Iemma | May 17, 2021 | News

PROVIDENCE, RI, May 17, 2021 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) announces the publication “Highly conserved, non-human-like, and cross-reactive SARS-CoV-2 T cell epitopes for COVID-19 vaccine design and validation” in NPJ Vaccines. This research identifies...

EpiVax Announces Participation in International Consortium for Development of Next-Generation Influenza Vaccines (INDIGO)

by Elena Iemma | Feb 17, 2021 | News

PROVIDENCE, RI, February 17, 2021 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) today announces its participation in the INDIGO consortium – a partnership of public and private research and development organizations from the EU, India, and United States (funded by the...

FDA Webinar: Epitope Selection for Cancer Vaccines

by Elena Iemma | Feb 17, 2021 | Events, Webinars

EpiVax CEO/CSO Annie De Groot hosted a talk for the FDA Office of Tissues and Advanced Therapies (OTAT) group on February 11, 2021. Annie presented the latest on EpiVax’s iVAX Toolkit in her talk “Epitope Selection for Cancer Vaccines”. JanusMatrix,...

World Vaccine and Immunotherapy Congress – Dec 2-5, 2019

by Annie De Groot | Nov 25, 2019 | Events, News

The annual World Vaccine and Immunotherapy Congress west coast meetings will be held on December 2-5, 2019 at the San Francisco Airport Marriott Waterfront Hotel Dr. Lenny Moise, the Director of Vaccine Research at EpiVax will be in attendance.  His talk:...